Radioimmunotherapy for glioblastoma

GBM is the most common and lethal malignant primary brain tumor in adults, and current standardof-care treatment has only limited therapeutic efficacy. We propose to develop and test a novel radioimmunotherapy strategy by rationally combining conformal radiation, a clinically translatable neoantigen nanovaccine, and immune checkpoint blockade to promote tumor response and prolong survival in an orthotopic preclinical GBM model. If successful, this novel treatment strategy could effectively treat or even cure GBM, and eventually prolong the overall survival rates of these patients.